Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice

Circulation

Volumn 112, Issue 4, 2005, Pages 553-562

  Song, Yanli ^a,c   Jones, John E ^a   Beppu, Hideyuki ^b   Keaney Jr , John F ^a   Loscalzo, Joseph ^a,c   Zhang, Ying Yi ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bone morphogenetic proteins; Hypertension, pulmonary; Inflammation; Thromboxane; Vasoconstriction

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOTHELIN 1; INTERLEUKIN 1BETA; PADGEM PROTEIN; PEPTIDOLEUKOTRIENE; PROSTACYCLIN; PROSTAGLANDIN E2; SEROTONIN; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC TRAIT; HEART RIGHT VENTRICLE PRESSURE; HETEROZYGOTE; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; INFLAMMATION; LIFESPAN; MALE; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STRESS; THROMBOCYTE ACTIVATION; TRANSGENE; URINE LEVEL; VIRUS RECOMBINANT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; DINOPROSTONE; GENE TRANSFER, HORIZONTAL; HETEROZYGOTE; HYPERTENSION, PULMONARY; INFLAMMATION; INTERLEUKIN-1; LUNG; MICE; MICE, INBRED C57BL; MUTATION; PLATELET ACTIVATION; SYSTOLE; THROMBOXANE A2;

EID: 23044504042     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.492488     Document Type: Article

References (39)

1. Urist MR. Bone: formation by autoinduction. Science. 1965;150: 893-899.
2. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Knz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242:1528-1534.
3. Massague J. The transforming growth factor-β family. Annu Rev Cell Mol. 1990;6:597-641.
4. Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 1994;8:133-146.
5. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996;10:1580-1594.
6. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000; 26:81-84.
7. Deng Z, Morse JH, Stager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67:737-744.
8. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet. 2000;37:741-745.
9. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S-12S.
10. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336: 111-117.
11. Peacock AJ. Primary pulmonary hypertension. Thorax. 1999;54: 1107-1118.
12. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361: 1533-1544.
13. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S. Coccolo F, Ventura C, Phillips JA 3rd, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004;43:33S-39S.
14. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA 3rd, Newman J, Williams D, Galie N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2001;68:92-102.
15. Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T, Miyazono K. BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol. 2000;221:249-258.
16. West J, Pagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res. 2004;94:1109-1114.
17. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest. 1998; 114:225S-230S.
18. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med. 1998;132:16-24.
19. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis. 2002;45:173-202.
20. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358-363.
21. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568-575.
22. Stenmark KR, James SL, Voelkel NF, Toews WH, Reeves JT, Murphy RC. Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. N Engl J Med. 1983;309:77-80.
23. Stenmark KR, Morganroth ML, Remigio LK, Voelkel NF, Murphy RC, Henson PM, Mathias MM, Reeves JT. Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. Am J Physiol. 1985;248:H859-H566.
24. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immuno-reactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;157:219-229.
25. Zhang YY, Walker JL, Huang A, Keaney JF, Clish CB, Serhan CN, Loscalzo J. Expression of 5-lipoxygenase in pulmonary artery endothelial cells. Biochem J. 2002;361-267-276.
26. Jones JE, Walker JL, Song Y, Weiss N, Cardoso WV, Tuder RM, Loscalzo J, Zhang YY. Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol. 2004; 286:H1775-H1784.
27. Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem. 1999;274:11660-11666.
28. Nusing R, Ullrich V. Immunoquantitation of thromboxane synthase in human tissues. Eicosanoids. 1990;3:175-180.
29. 2 synthase in normal and LPS-primed lungs. Am J Physiol Lung Cell Mol Physiol. 2000;278: L744-L753.
30. Zhao GQ. Consequences of knocking out BMP signaling in the mouse. Genesis. 2003;35:43-56.
31. Barst RJ, Stalcup SA, Steeg CN, Hall JC, Frosolono MF, Cato AE, Mellins RB. Relation of arachidonate metabolites to abnormal control of the pulmonary circulation in a child. Am Rev Respir Dis. 1985;131:171-177.
32. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
33. 2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation. 1993;88:2117-2122.
34. Ullrich V, Nusing R. Thromboxane synthase: from isolation to function. Stroke. 1990;21(suppl IV):IV-134-IV-138.
35. Lee MJ, Yang CW, Jin DC, Chang YS, Bang BK, Kim YS. Bone morphogenetic protein-7 inhibits constitutive and interleukin-1β-induced monocyte chemoattractant protein-1 expression in human mesangial cells: role for JNK/AP-1 pathway. J Immunol. 2003;170:2557-2563.
36. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72:2994-2998.
37. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem. 1978;47:997-1029.
38. + channels and pulmonary vasoconstriction: role of protein kinase Cζ. Circ Res. 2003;93: 656-663.
39. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 1997;96:2280-2286.